Hormonal
RORs (RORα and RORγ) function as intermediaries linking the circadian clock machinery to the regulation of lipid and glucose metabolism, suggesting that circadian disruption may contribute to metabolic syndrome.
Maintaining a consistent sleep schedule and minimizing nighttime light exposure may support healthy metabolic function by aligning with your body's natural circadian rhythms. This alignment helps regulate genes involved in lipid and glucose metabolism, potentially reducing the risk of metabolic syndrome.
Recent studies indicated that RORs provide an important link between the circadian clock machinery and its regulation of metabolic genes and metabolic syndrome... RORs appear to be part of the mechanism that links the circadian clock to its regulation of lipid/glucose homeostasis, inflammation, and insulin resistance.
Why this rating
Evidence is derived from molecular biology studies in mice and cell lines, showing regulatory interactions between clock genes and RORs.
Source
Retinoic acid-related orphan receptors α and γ: key regulators of lipid/glucose metabolism, inflammation, and insulin sensitivity
Anton M. Jetten et al. · Frontiers in Endocrinology · 2013
DOI 10.3389/fendo.2013.00001
More from this paper
- Deficiency or inhibition of the nuclear receptor RORα protects against diet- and age-induced obesity, hepatosteatosis, and insulin resistance by increasing energy expenditure and suppressing pro-inflammatory gene expression in adipose tissue.Moderate
- Deficiency or inhibition of the nuclear receptor RORγ1 protects against diet-induced insulin resistance and improves glucose tolerance, potentially through mechanisms distinct from RORα.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →